In vivo, male wister rats aged 7–8 weeks were used to make collagen induced arthritis (CIA) disease model [
31]. It is injected into the tail root of wister rats through bovine type Ⅱ collagen and emulsifier of incomplete Freund adjuvant. CIA wister rat model was established after 2 weeks of immune induction, we made a general observation and evaluated the arthritis index, and then injected drugs into the diseased joints to ensure that the drug concentration was 500 nmol/L tFNAs. Similarly, the ratio of tFNAs: nobiletin was 1:80, and the control group was injected with normal saline. The drug was injected into ankles every other day for 2 weeks/6 times and joint samples were collected for histopathological evaluation. The experiment showed that the joints of CIA rats are significantly red and swollen. Injection of tFNAs cannot alleviate the lesions, but both nobiletin group and tFNA-Nob group could alleviate the arthritis lesions to a certain extent, and the effect of tFNA-Nob group was better (
Fig. 4a). Hematoxylin-eosin (HE) staining found that the synovial tissue at the joints of CIA rats significantly proliferated, thickened, invaded bone tissue and cartilage, and more inflammatory cells were seen. After treatment with tFNAs, nobiletin and tFNA-Nob, tFNAs group had almost no therapeutic effect. Nobiletin and tFNA-Nob had a certain therapeutic effect, and the therapeutic effect of tFNA-Nob was the best (
Fig. 4b). Toluidine blue staining (TB) showed that the bone tissue and cartilage tissue of CIA rats were damaged, and tFNA-Nob had a good recovery effect after treatment (
Fig. 4c). Masson staining demonstrated that the degree of fibrosis of CIA rats' joints was seriously increased, and the bone tissue was damaged by inflammation (
Fig. 4d). Then we further carried out TdT-mediated dUTP Nick-End Labeling (TUNEL) staining on the joint synovium. Compared with normal rats, CIA rats have fewer apoptotic cells, thicker synovium and increased number of synovial fibroblast, while after the three groups of drug treatment, the thickness of synovium and number of synovial fibroblast decreased. tFNAs could not promote apoptosis, and tFNA-Nob promoted the number of apoptotic cells to increase significantly, which was consistent with the drug regulation on the apoptosis behavior of two different synovial cells in the cell experiment (
Fig. 4e). Previous studies have proved that inflammatory immune response can promote osteoclast formation, inhibit osteoblast formation, destroy the balance between osteoclasts and osteoblasts, and lead to bone resorption [
32]. In this experiment, tFNA-Nob inhibited inflammation by promoting synovial tissue apoptosis, alleviated the immune cascade, antagonized the secretion of inflammatory factors, regulated activated osteoclasts (Figs. S5e and f in Supporting information). As a result, the destruction of bone and joint was relieved, and the reduced bone mineral density and bone volume fraction tend to be normal (Figs. S5c and d in Supporting information). This study was approved by the Ethics Committee of The West China Hospital of Stomatology, Sichuan University. tFNA-Nob efficiently transmitted the nobiletin into the synovial tissue of the diseased joint. As a carrier with tissue permeability and cell penetrating ability, tFNAs improved the bioavailability of nobiletin, nobiletin was released slowly and stably and exerted its pharmacological effects of promoting apoptosis and anti-inflammatory, induced the apoptosis of abnormally proliferating synovial cells and reduced the secretion of inflammatory proteins, thus protecting soft tissue and bone tissue in joint, reducing arthritis score and alleviating rheumatoid arthritis (Figs. S5a and b in Supporting information,
Fig. 4a). Compared with the same concentration of nobiletin, tFNA-Nob can significantly reduce the course of arthritis in CIA rats.